
## Gregoire Wuerzner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5470448/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cortical perfusion as assessed with contrast-enhanced ultrasound is lower in patients with chronic kidney disease than in healthy subjects but increases under low salt conditions. Nephrology Dialysis Transplantation, 2022, 37, 705-712.	0.7	8
2	Acute decrease of urine calcium by amiloride in healthy volunteers under high-sodium diet. Nephrology Dialysis Transplantation, 2022, 37, 298-303.	0.7	1
3	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2022, 15, 31-42.	2.9	14
4	Kinetics of neuropeptide Y, catecholamines, and physiological responses during moderate and heavy intensity exercises. Neuropeptides, 2022, 92, 102232.	2.2	6
5	Accurate Location of Catheter Tip With the Free-to-Total Metanephrine Ratio During Adrenal Vein Sampling. Frontiers in Endocrinology, 2022, 13, 842968.	3.5	4
6	Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects. Frontiers in Cardiovascular Medicine, 2022, 9, 854230.	2.4	8
7	Implanted System for Orthostatic Hypotension in Multiple-System Atrophy. New England Journal of Medicine, 2022, 386, 1339-1344.	27.0	17
8	Defining intradialytic hypertension: the importance of measuring blood pressure accurately. Nephrology Dialysis Transplantation, 2022, 37, 1783-1785.	0.7	2
9	New Aspects in the Management of Hypertension in Patients with Chronic Kidney Disease not on Renal Replacement Therapy. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 125-135.	2.2	2
10	Guidance for the Interpretation of Continual Cuffless Blood Pressure Data for the Diagnosis and Management of Hypertension. Frontiers in Medical Technology, 2022, 4, .	2.5	12
11	Contrast-Enhanced Ultrasonography Enables the Detection of a Cold Pressor Test-Induced Increase in Renal Microcirculation in Healthy Participants. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	3
12	Cuffless blood pressure measuring devices: review and statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. Journal of Hypertension, 2022, 40, 1449-1460.	0.5	65
13	High blood pressure screening in pharmacies during May Measurement Month campaigns in Switzerland. Blood Pressure, 2022, 31, 129-138.	1.5	1
14	Impact of obesity with or without hypertension on systemic haemodynamic and renal responses to lower body negative pressure. Blood Pressure, 2021, 30, 67-74.	1.5	2
15	Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet. Clinical Pharmacology and Therapeutics, 2021, 109, 746-753.	4.7	14
16	How Do I Manage Hypertension in Patients with Advanced Chronic Kidney Disease Not on Dialysis? Perspectives from Clinical Practice. Vascular Health and Risk Management, 2021, Volume 17, 1-11.	2.3	10
17	Interprofessional Medication Adherence Program for Patients With Diabetic Kidney Disease: Protocol for a Randomized Controlled and Qualitative Study (PANDIA-IRIS). JMIR Research Protocols, 2021, 10, e25966.	1.0	5
18	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. Nephrology Dialysis Transplantation, 2021, 36, 1326-1346.	0.7	18

#	Article	IF	CITATIONS
19	Blood pressure from the optical Aktiia Bracelet: a 1-month validation study using an extended ISO81060-2 protocol adapted for a cuffless wrist device. Blood Pressure Monitoring, 2021, 26, 305-311.	0.8	40
20	SMARTPHONE-BASED BLOOD PRESSURE MEASUREMENTS VALIDATION USING THE AAMI/ESH/ISO UNIVERSAL PROTOCOL: RESULTS FROM THE FIRST FORTY PATIENTS. Journal of Hypertension, 2021, 39, e130-e131.	0.5	0
21	IS AUSCULTATION ADEQUATE TO ESTIMATE BLOOD PRESSURE RESPONSES RELATED TO BODY POSITION CHANGES?. Journal of Hypertension, 2021, 39, e130.	0.5	0
22	BLOOD PRESSURE FROM THE OPTICAL AKTIIA BRACELET: A ONE MONTH VALIDATION STUDY USING AN ADAPTED ISO81060-2 PROTOCOL. Journal of Hypertension, 2021, 39, e133-e134.	0.5	1
23	Hypertension in kidney transplantation: a consensus statement of the â€ <sup>~</sup> hypertension and the kidney' working group of the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1513-1521.	0.5	16
24	Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination. Hypertension, 2021, 77, e56-e57.	2.7	59
25	Smartphone based blood pressure measurement: accuracy of the OptiBP mobile application according to the AAMI/ESH/ISO universal validation protocol. Blood Pressure Monitoring, 2021, 26, 441-448.	0.8	25
26	Assessment of a strategy combining ambulatory blood pressure, adherence monitoring and a standardised triple therapy in resistant hypertension. Blood Pressure, 2021, 30, 332-340.	1.5	1
27	Sodium Intake as a Cardiovascular Risk Factor: A Narrative Review. Nutrients, 2021, 13, 3177.	4.1	24
28	Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension. Hypertension, 2021, 78, 898-911.	2.7	12
29	Team-Based Care for Improving Hypertension Management: A Pragmatic Randomized Controlled Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 760662.	2.4	6
30	Validation of the optical Aktiia bracelet in different body positions for the persistent monitoring of blood pressure. Scientific Reports, 2021, 11, 20644.	3.3	19
31	Bariatric Surgery Induces a Differential Effect on Plasma Aldosterone in Comparison to Dietary Advice Alone. Frontiers in Endocrinology, 2021, 12, 745045.	3.5	4
32	Hypertension artérielle. Revue Medicale Suisse, 2021, 17, 192-195.	0.0	0
33	Hypertension artérielle sévère ou urgence hypertensive : du cabinet à l'hôpital. Revue Medicale Suiss 2021, 17, 1549-1555.	<sup>se</sup> ð.0	0
34	Hypertension après transplantation rénale. Revue Medicale Suisse, 2021, 17, 1571-1574.	0.0	0
35	Hypertension : faut-il aborder les effets indésirables possibles des médicaments avec nos patients ?. Revue Medicale Suisse, 2021, 17, 1547-1547.	0.0	0
36	Comparative effectiveness of different antihypertensive agents in kidney transplantation: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2020, 35, 878-887.	0.7	32

#	Article	IF	CITATIONS
37	Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS. Analytical Chemistry, 2020, 92, 859-866.	6.5	10
38	Blood pressure measurements with the OptiBP smartphone app validated against reference auscultatory measurements. Scientific Reports, 2020, 10, 17827.	3.3	41
39	P0677CONTRAST-ENHANCED ULTRASOUND TO ASSESS RENAL MICROCIRCULATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
40	Is auscultation an issue when validating 24-h blood pressure monitoring devices?. Blood Pressure Monitoring, 2020, 25, 301-302.	0.8	3
41	Brainstem Correlates of a Cold Pressor Test Measured by Ultra-High Field fMRI. Frontiers in Neuroscience, 2020, 14, 39.	2.8	12
42	Hypertension and Drug Adherence in the Elderly. Frontiers in Cardiovascular Medicine, 2020, 7, 49.	2.4	41
43	Renal Parenchymal Disease. Updates in Hypertension and Cardiovascular Protection, 2020, , 1-19.	0.1	0
44	Abstract P192: Is Auscultation Adequate To Estimate Blood Pressure Responses Related To Body Position Changes?. Hypertension, 2020, 76, .	2.7	0
45	Docteur, moi je suis contre les médicamentsâ€!. Revue Medicale Suisse, 2020, 16, 1671-1671.	0.0	Ο
46	Déprescription dans le contexte de l'hypertension. Revue Medicale Suisse, 2020, 16, 1690-1692.	0.0	0
47	Les bloqueurs du système rénine-angiotensine-aldostérone en temps de pandémie Covid-19â€: amis ou ennemis�. Revue Medicale Suisse, 2020, 16, 1003-1007.	0.0	Ο
48	Hypertension artérielle. Revue Medicale Suisse, 2020, 16, 53-54.	0.0	0
49	Hypertension artérielle et cancerâ€: une relation étroite à ne pas oublier. Revue Medicale Suisse, 2020, 16, 1680-1683.	0.0	0
50	Des changements en vue…. Revue Medicale Suisse, 2020, 16, 387-388.	0.0	0
51	Is blood pressure measured correctly in dialysis centres? Physicians' and patients' views. Nephrology Dialysis Transplantation, 2019, 34, 1612-1615.	0.7	6
52	Sex and Body Mass Index Modify the Association Between Leptin and Sodium Excretion: A Cross-sectional Study in an African Population. American Journal of Hypertension, 2019, 32, 1101-1108.	2.0	2
53	FP760COMPARATIVE EFFECTIVENESS OF DIFFERENT ANTIHYPERTENSIVE AGENTS IN KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
54	Hypertension de la personne âgéeâ€: les nouvelles recommandations sont-elles changé la prise en charge�. Revue Medicale Suisse, 2019, 15, 1597-1602.	0.0	0

#	Article	IF	CITATIONS
55	Hypertension artérielle et syndrome des apnées obstructives du sommeilâ€: état des connaissances. Revue Medicale Suisse, 2019, 15, 1620-1624.	0.0	2
56	Hypertension artérielle. Revue Medicale Suisse, 2019, 15, 57-61.	0.0	0
57	Quand le patient devient une cible, comment faire�. Revue Medicale Suisse, 2019, 15, 1595-1595.	0.0	0
58	Blood pressure response to renal denervation is correlated with baseline blood pressure variability. Journal of Hypertension, 2018, 36, 221-229.	0.5	20
59	Use of oscillometric devices in atrial fibrillation: a comparison of three devices and invasive blood pressure measurement. Blood Pressure, 2018, 27, 48-55.	1.5	19
60	Prevalence of Hypertensive Phenotypes After Preeclampsia. Hypertension, 2018, 71, 103-109.	2.7	55
61	May Measurement Month 2017: an analysis of blood pressure screening results worldwide. The Lancet Global Health, 2018, 6, e736-e743.	6.3	245
62	Blood Pressure and Renal Responses to Orthostatic Stress Before and After Radiofrequency Renal Denervation in Patients with Resistant Hypertension. Frontiers in Cardiovascular Medicine, 2018, 5, 42.	2.4	6
63	Qualitative Assessments of Adherence. Updates in Hypertension and Cardiovascular Protection, 2018, , 11-19.	0.1	2
64	Recommandations américaines sous haute tension. Revue Medicale Suisse, 2018, 14, 1594-1597.	0.0	0
65	Stratégies de prévention cardiovasculaire au cabinet. Revue Medicale Suisse, 2018, 14, 488-492.	0.0	0
66	Prise en charge de l'hypertension artérielle : de l'inertie thérapeutique à l'autonomie des patients Revue Medicale Suisse, 2018, 14, 1602-1605.	<sup>5.</sup> 0.0	0
67	Prise en charge de l'hypertension artérielle. Revue Medicale Suisse, 2018, 14, 46-48.	0.0	0
68	Nouvelles cibles tensionnelles : beaucoup de bruit pour rien ?. Revue Medicale Suisse, 2018, 14, 1579-1579.	0.0	0
69	Hypertension artérielle diastolique isolée : faut-il encore s'en préoccuper ?. Revue Medicale Suisse, 2018, 14, 1607-1610.	0.0	3
70	Team-based care for improving hypertension management among outpatients (TBC-HTA): study protocol for a pragmatic randomized controlled trial. BMC Cardiovascular Disorders, 2017, 17, 39.	1.7	17
71	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*, Nephrology Dialysis Transplantation, 2017, 32, 620-640.	0.7	133
72	Hypertension in dialysis patients. Journal of Hypertension, 2017, 35, 657-676.	0.5	56

#	Article	IF	CITATIONS
73	Optimizing hypertension management in renal transplantation. Journal of Hypertension, 2017, 35, 2335-2338.	0.5	5
74	Optimizing hypertension management in renal transplantation: a call to action. Nephrology Dialysis Transplantation, 2017, 32, 1959-1962.	0.7	14
75	MP120THE URINARY UROMODULLIN CREATININE RATIO IS DECREASED 6 WEEKS POST-PARTUM IN WOMEN WITH PREECLAMPSIA. Nephrology Dialysis Transplantation, 2017, 32, iii472-iii472.	0.7	0
76	Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring. Frontiers in Pharmacology, 2017, 8, 738.	3.5	2
77	Correction: Chronic kidney disease: Should sodium intake be restricted in patients with CKD?. Nature Reviews Nephrology, 2016, 12, 666-666.	9.6	2
78	Effect of longâ€ŧerm adherence to clopidogrel on the VASPâ€PRI after elective coronary stent implantation: a randomized controlled study. British Journal of Clinical Pharmacology, 2016, 82, 1486-1497.	2.4	6
79	Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes. European Journal of Nutrition, 2016, 55, 1089-1097.	3.9	45
80	Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infectious Diseases, The, 2016, 16, 311-320.	9.1	133
81	Physiologic Control of the Circadian Variability in Blood Pressure. , 2016, , 149-163.		1
82	Adherence to Medications in Uncontrolled Hypertension. Updates in Hypertension and Cardiovascular Protection, 2016, , 179-192.	0.1	0
83	Drug adherence monitoring in clinical trials. Journal of Hypertension, 2015, 33, 2395-2398.	0.5	8
84	Salt, blood pressure and cardiovascular risk: what is the most adequate preventive strategy? A Swiss perspective. Frontiers in Physiology, 2015, 6, 227.	2.8	22
85	Pathophysiology of Hypertension. , 2015, , 655-683.		3
86	Drug adherence in chronic kidney diseases and dialysis. Nephrology Dialysis Transplantation, 2015, 30, 39-44.	0.7	93
87	What Is the Hypertension "Phenotype�. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	4
88	Furosemide stimulation of parathormone in humans: role of the calcium-sensing receptor and the renin-angiotensin system. Pflugers Archiv European Journal of Physiology, 2015, 467, 2413-2421.	2.8	10
89	Epidemiology of Masked and White-Coat Hypertension: The Family-Based SKIPOGH Study. PLoS ONE, 2014, 9, e92522.	2.5	56
90	Eligibility for Renal Denervation. Hypertension, 2014, 63, 1319-1325.	2.7	61

#	Article	IF	CITATIONS
91	Blood Pressure and Physical Activity: Time to Move (On). American Journal of Hypertension, 2014, 27, 1125-1125.	2.0	0
92	Ambulatory Blood Pressure and Adherence Monitoring: Diagnosing Pseudoresistant Hypertension. Seminars in Nephrology, 2014, 34, 498-505.	1.6	15
93	Response to Maximizing Treatment Adherence: Physician–Patient Partnerships vs Procedures. Hypertension, 2014, 63, e8.	2.7	0
94	State-of-the-art treatment of hypertension: established and new drugs. European Heart Journal, 2014, 35, 557-562.	2.2	30
95	Circadian glomerular function: from physiology to molecular and therapeutical aspects. Nephrology Dialysis Transplantation, 2014, 29, 1475-1480.	0.7	31
96	Should sodium intake be restricted in patients with CKD?. Nature Reviews Nephrology, 2014, 10, 363-364.	9.6	4
97	Hypertension in Chronic Kidney Disease – Role of Arterial Calcification and Impact on Treatment. European Cardiology Review, 2014, 9, 115.	2.2	15
98	Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus. Swiss Medical Weekly, 2014, 144, w13913.	1.6	6
99	Blockade of the Renin-Angiotensin System in Hypertensive Patients with Atherosclerotic Renal Artery Stenosis. Current Hypertension Reports, 2013, 15, 497-505.	3.5	0
100	Blockade of the renin–angiotensin system and renal tissue oxygenation as measured with BOLD-MRI in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2013, 99, 136-144.	2.8	38
101	Measuring, Analyzing, and Managing Drug Adherence in Resistant Hypertension. Hypertension, 2013, 62, 218-225.	2.7	189
102	Effect of Contrasted Sodium Diets on the Pharmacokinetics and Pharmacodynamic Effects of Renin–Angiotensin System Blockers. Hypertension, 2013, 61, 1239-1245.	2.7	8
103	Step Count is Associated With Lower Nighttime Systolic Blood Pressure and Increased Dipping. American Journal of Hypertension, 2013, 26, 527-534.	2.0	18
104	Response to "Assessment of Blood Pressure Dipping: Is the Evaluation Method Important?". American Journal of Hypertension, 2013, 26, 1054-1054.	2.0	1
105	Clinical Benefits of an Adherence Monitoring Program in the Management of Secondary Hyperparathyroidism with Cinacalcet: Results of a Prospective Randomized Controlled Study. BioMed Research International, 2013, 2013, 1-8.	1.9	23
106	Treatment of Resistant Hypertension. Which Additional Antihypertensive Drugs?. , 2013, , 115-126.		2
107	Renal perfusion evaluation with contrast-enhanced ultrasonography. Nephrology Dialysis Transplantation, 2012, 27, 674-681.	0.7	73
108	Short-Term Increase in Particulate Matter Blunts Nocturnal Blood Pressure Dipping and Daytime Urinary Sodium Excretion. Hypertension, 2012, 60, 1061-1069.	2.7	61

#	Article	IF	CITATIONS
109	Should Hypertensive Patients Take Vitamin D?. Current Hypertension Reports, 2012, 14, 318-323.	3.5	8
110	Pharmacokinetic evaluation of losartan. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 643-649.	3.3	24
111	Critical review of cancer risk associated with angiotensin receptor blocker therapy. Vascular Health and Risk Management, 2011, 7, 741.	2.3	11
112	Long-term use and tolerability of irbesartan for control of hypertension. Integrated Blood Pressure Control, 2011, 4, 17.	1.2	21
113	Antinatriuretic Effect of Vasopressin in Humans Is Amiloride Sensitive, Thus ENaC Dependent. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 753-759.	4.5	26
114	Lowering systolic blood pressure below 130 mm Hg does not improve cardiovascular outcomes in hypertensive patients with diabetes and coronary artery disease. Evidence-Based Medicine, 2011, 16, 24-26.	0.6	4
115	Measurement of Glomerular Filtration Rate in Obese Patients: Pitfalls and Potential Consequences on Drug Therapy. Obesity Facts, 2011, 4, 238-243.	3.4	33
116	A new technique for simultaneous validation of two manual nonmercury auscultatory sphygmomanometers (A&D UM-101 and Accoson Greenlight 300) based on the International protocol. Blood Pressure Monitoring, 2010, 15, 322-325.	0.8	14
117	Marked Association Between Obesity and Glomerular Hyperfiltration: A Cross-sectional Study in an African Population. American Journal of Kidney Diseases, 2010, 56, 303-312.	1.9	118
118	IEF pattern classificationâ€derived criteria for the identification of epoetinâ€Î´ in urine. Electrophoresis, 2010, 31, 1918-1924.	2.4	11
119	Effect of Sodium Loading/Depletion on Renal Oxygenation in Young Normotensive and Hypertensive Men. Hypertension, 2010, 55, 1116-1122.	2.7	69
120	Treating high blood pressure: Is reaching the target more important than the means? No, the means are important. European Journal of Internal Medicine, 2010, 21, 478-483.	2.2	0
121	Direct analysis of valsartan or candesartan in human plasma and urines by on-line solid phase extraction coupled to electrospray tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 919-926.	2.3	36
122	Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 981-987.	3.3	16
123	The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans. Journal of Hypertension, 2009, 27, 1404-1409.	0.5	29
124	RENIN INHIBITION WITH ALISKIREN. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 426-430.	1.9	15
125	Rationale for Combining Blockers of the Renin-Angiotensin System. Seminars in Nephrology, 2007, 27, 544-554.	1.6	10
126	Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring. European Journal of Clinical Pharmacology, 2007, 63, 1179-1184.	1.9	42

#	Article	IF	CITATIONS
127	Effects of selective angiotensin II and β1-receptor blockade on renal haemodynamics and sodium handling during orthostatic stress in healthy individuals. Journal of Hypertension, 2006, 24, S89-S93.	0.5	8
128	Metoprolol prevents sodium retention induced by lower body negative pressure in healthy men. Kidney International, 2005, 68, 688-694.	5.2	8
129	Angiotensin II receptor blockade prevents acute renal sodium retention induced by low levels of orthostatic stress. Kidney International, 2004, 65, 238-244.	5.2	9
130	Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100). Hypertension, 2002, 39, E1-8.	2.7	376
131	Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor SPP100; Comparison with Enalapril. Hypertension, 2000, 36, 695-695.	2.7	0